Exosome-targeted DNA vaccine
AssigneeExorphia, Inc.
InventorsKen Ishii, Kouji Kobiyama, Tomohiro Kanuma
Life of this patent
Estimating the term…
Abstract
In order to further increase antigenicity to provide a DNA vaccine which is clinically usable in humans, the inventors of the present invention focused on exosomes, which are garnering attention as tools for DDS, and discovered that an exosome expressing a fusion antigen of an exosome (extracellular microparticle)-constituent protein and a vaccine antigen has excellent cytotoxic T-cell inducibility. Consequently, the present invention provides a nucleic acid constituent including a nucleic acid sequence coding for an exosome marker protein and a nucleic acid sequence coding for a vaccine antigen.
Claims20
A nucleic acid construct comprising a nucleic acid sequence encoding an exosome marker protein and a nucleic acid sequence encoding a vaccine antigen, wherein the exosome marker protein and the vaccine antigen are expressed in a fused form.
A protein in a form of a vaccine antigen protein fused with an exosome marker protein.
An exosome comprising a vaccine antigen protein and an exosome marker protein in a fused form.
Dependencies are inferred from the claim text.